Canada Approves Seattle Genetics' Adcetris
Seattle Genetics recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin).
Seattle Genetics recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin).
A WOMAN from Teesside has become the 1,000th patient to undergo transplantation of her own bone marrow stem cells at the Freeman Hospital, in Newcastle.
Drugmaker Bristol-Myers Squibb Inc. said Thursday that its fourth-quarter profit rose 8.6 percent, as reduced production and marketing costs and a big tax benefit offset a plunge in Plavix sales due to …
Senior GymDawg Kylie Sharp is the first known college student-athlete to compete with two chronic liver diseases that will require a transplant. This is her remarkable story of the Huskies teamwork that made her dream possible.
Earl Martinez hopes his “Need Kidney Donor” sign will soon lead to a transplant.
Galectin Therapeutics , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.
Dennis Koerner would embrace the opportunity to be coaching against former McHenry football coach Mike Noll’s powerhouse teams of 20 years ago.
This piece was written by Ron Cohen, the chief executive of Acorda Therapeutics. Cohen founded Acorda Therapeutics, Inc. in 1995. Before that, he was an officer at Advanced Tissue Sciences,a pioneering biotech in the growth of human organ tissues for transplant. He received his M.D. from the Columbia College of Physicians & Surgeons and completed his residency in Internal Medicine at the …
It may sound like the most unappealing treatment available, but a small new study has concluded that inserting fecal material from a healthy person into the gut of someone with severe diarrhea may cure their problem more effectively than antibiotics.
For the nearly 30 million Americans who suffer from a rare disease, there’s heartening news: Drugmakers have been shifting much of their research away from pills for the millions to uncommon disorders …